Mp07-05 outcomes of anastrozole in the treatment of subfertile males with body mass index ≥ kg/m2

Paternal obesity has been shown to have a negative impact on male fertility possibly due to increased aromatase activity from excess adipose tissue leading to decreased testosterone levels. Anastrozole, a non-steroidal aromatase enzyme competitive inhibitor, can increase endogenous testosterone production and has been associated with improved sperm counts. We sought to determine the outcomes of anastrozole therapy in the treatment of overweight or obese, sub-fertile males.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Infertility: Therapy II Source Type: research